To study the risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease in central India

Ankita Kondhalkar; Ranjit Ambad; Neha Bhatt; Roshan Kumar Jha

doi:10.53730/ijhs.v6nS2.5021

Authors

Ankita Kondhalkar Tutor (PhD Scholar) Dept. of Biochemistry Datta Meghe Medical College, Nagpur, India
Ranjit Ambad Associate Professor Dept. of Biochemistry Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre Nagpur, India -441110 (Datta Meghe Institute of Medical Sciences)
Neha Bhatt Assistant Professor Dept. of Pathology Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre Nagpur, India -441110 (Datta Meghe Institute of Medical Sciences)
Roshan Kumar Jha Tutor Dept. of Biochemistry Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences Sawangi (Meghe), Wardha, India -442001

Keywords:

GST-π, HCC, hepatitis, liver cancer, NAFLD, outcome

Abstract

common cancer and the third leading cause of cancer-related deaths. A known risk factor for HCC is non-alcoholic fatty liver disease (NAFLD), a continuum of hepatic disorders related to obesity and the metabolic syndrome. AIM: We conducted an observational study to identify risk factors for hepatocellular cancer in patients with non-alcoholic fatty liver disease who came to SMHRC Nagpur for a routine visit. MATERIAL AND METHODS: The study included 300 people aged 35 to 85 years old who visited Shalinitai Meghe hospital in Nagpur for a health check-up. We were able to keep the two groups apart here. The control group is made up of alcoholics with fatty liver, while the study group is made up of non-alcoholics with fatty liver. Each community consists of 150 patients. A quantitative diagnostic kit was used to analyse liver function and lipid profile analyses, which were then examined using a photometric process. The enzyme related immunosorbant assay was used to detect glutathione s transferase pi. RESULTS: Non-alcoholic fatty liver had greater LFT than alcoholic fatty liver in the control group, according to the report.

Downloads

Download data is not yet available.

References

Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696- 703

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.

Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.

Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. HEPATOLOGY 2002;35:746-752.

Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710- 723.

D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Estimating the world cancer burden: Globocan 2000,” International Journal of Cancer, 2001; 94( 2), 153–156.

J. Bruix and M. Sherman, “Management of hepatocellular carcinoma,” Hepatology, 2005;42(5), 1208–1236.

H. B. El-Serag, “Hepatocellular carcinoma: recent trends in the United States,” Gastroenterology, 2004,127(5), 27–34.

E. Bugianesi, N. Leone, E. Vanni et al., “Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma,” Gastroenterology, 2002

; 123(1), 134–140.

A.J. McCullough, “The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease,” Clinics in Liver Disease, 2004;8(3), 521–533.

Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30

Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014;60:110-7.

Cho EJ, Kwack MS, Jang ES, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011;84 (1):17-22

Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155-66

Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842-845

Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. HEPATOLOGY 2000;32:3-10.

Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-1664.

Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. HEPATOLOGY 1999;29:1131-1138.

Boyer TD. The glutathione S-transferases: an update. Hepatology 1989; 9: 486–96.

Metwally MA, Zein CO, Zein NN. Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 2007;52:582-588

Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-1231.

Hirano T, Kaplowitz N, Tsukamoto H, Kamimura S, Fernandez-Checa JC. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology 1992; 16: 1423–7.

Pardhe BD, Shakya S, Bhetwal A, Mathias J, Khanal PR, Pandit R, et al. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal. BMC Gastroenterol. 2018;18:109.

Novakovic T, Mekic M, Smilic L, Smilic T, Inić-Kostic B, Jovicevic L, et al. Anthropometric and biochemical characteristics of patients with nonalcoholic fatty liver diagnosed by non-invasive diagnostic methods. Med Arch. 2014;68:22–6.

Santhoshakumari TMJ, Radhika G, Kanagavalli P. A study of anthropometric and lipid profile parameters in non-alcoholic fatty liver disease patients attending a tertiary care hospital at puducherry. IOSR J Dent Med Sci (IOSR-JDMS) 2017;16:33–7

Shinde R. A Prospective Observational Case Series of Liver Injury in Paediatric Patients Secondary to Consumption of Ayurvedic Herbomineral Formulations. Indian Journal of Forensic Medicine & Toxicology, October-December 2020, Vol. 14, No. 4; 7121-7125.

Ain P, Parate R, Dubey T, Jain R. Prevalence of NAFLD (non-alcoholic fatty liver disease) in metabolic syndrome and their correlation with various biochemical and serologic parameters for early detection and detecting patients of Non-alcoholic steatohepatitis Prevalence. 2018;3:24–8.

Harada S, Abei M, Tanaka N, Agarwal DP, Goedde HW. Liver glutathione S-transferase polymorphism in Japanese and its pharmacogenetic importance. Hum Genet 1987; 75: 322-5.

Harrison DJ, Hayes PC. Immunolocalisation of glutathione S-transferases in human renal and liver diseases. In: Hayes JD, Hayes PC, Mantle TJ, Pickett CB, eds. Glutathione S-transferase and drug resistance. London: Taylor and Francis, 1990: 431-41.

Howie AF, Forrester LM, Glancy MJ et al. Glutathione S-transferase and glutathione peroxidase in human tumors. Carcinogenesis 1990; 11: 451-8.